DAA treatment costs hit $6bn as some HCV patients are reinfected up to four times
By Michael Woodhead
24 Jan 2020
The cost of treating hepatitis C with PBS-listed direct acting antivirals (DAAs) has reached almost $6 billion, new government figures show. When DAAs were listed on the PBS in March 2016, the then health minister Sussan Ley said the government had budgeted $1.3 billion to subsidise the drugs that would otherwise cost up to $50,000 ...